Destiny Pharma plc (DEST.L)
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Company Info
Highlights
£2.87M
-£0.06
£1.55 - £44.88
£46.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in Destiny Pharma plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
DEST.L
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
2.90%
3.70%
10.94%
22.18%
12.41%
11.21%
Monthly Returns
The table below presents the monthly returns of DEST.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -17.86% | -43.48% | -21.54% | -30.39% | -11.27% | -44.44% | -71.14% | -95.71% | |||||
| 2023 | -4.67% | -34.31% | -17.16% | 19.64% | -10.24% | -10.07% | 71.64% | 16.30% | -4.67% | 2.94% | 21.90% | 9.37% | 30.84% |
| 2022 | -17.22% | -17.92% | -29.58% | -3.00% | -7.22% | -8.89% | 15.85% | -16.84% | -11.39% | 11.43% | -19.87% | 71.20% | -48.80% |
| 2021 | 68.61% | 0.00% | 44.59% | -12.87% | -3.78% | -9.29% | -11.02% | 7.52% | -4.12% | -2.58% | 2.64% | -10.30% | 52.55% |
| 2020 | -5.81% | -12.35% | -8.45% | 21.54% | -11.39% | 7.14% | -8.00% | 40.58% | 14.43% | 82.88% | -35.96% | 5.38% | 59.30% |
| 2019 | 29.03% | -1.25% | 5.06% | -2.41% | -2.47% | -0.63% | -18.15% | -42.41% | 6.76% | 3.80% | 1.22% | 3.61% | -30.65% |
| 2018 | -3.51% | -1.09% | -13.97% | 6.84% | -9.20% | -6.17% | -1.41% | -16.67% | -0.57% | -16.09% | -6.16% | -9.49% | -56.49% |
| 2017 | -28.28% | -17.31% | -10.85% | 23.91% | -34.48% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of DEST.L is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Destiny Pharma plc (DEST.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Destiny Pharma plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Destiny Pharma plc was 99.04%, occurring on Jul 26, 2024. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.04% | Sep 6, 2017 | 1737 | Jul 26, 2024 | — | — | — |
Volatility
Volatility Chart
The current Destiny Pharma plc volatility is 134.66%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Destiny Pharma plc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |